A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes
mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors …

This systematic review addresses the central research question,“what is known from the
published, peer‐reviewed literature about the impact of diabetes on the risk of bacterial …

Cardiovascular disease is the leading cause of death in women. Despite recognition of sex-
specific differences in cardiovascular health, females are underrepresented across all …

Background Sodium‐glucose cotransporter‐2 inhibitor (SGLT2I) use has increased among
community‐dwelling populations, but little is known about how clinicians have prescribed …

Purpose Asymptomatic pyuria and bacteriuria are more prevalent in diabetic patients and
may be associated with urinary tract infection (UTI). The aim of this study is to investigate the …

Abstract Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce
adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality …

Cardiovascular disease (CVD) and kidney disease are the main causes of morbidity and
mortality in type 2 diabetes mellitus (T2DM). Globally, the incidence of T2DM continues to …

Biological sex is one of the major factors characterizing the heart failure (HF) patient
phenotype. Understanding sex-related differences in HF is crucial to implement …

Background: Patients with type 2 diabetes (T2D) are at an increased risk of genital urinary
(GU) infections, with the risk increasing with higher A1Cs. Given the broad adoption of …

Sodium glucose co-transporter 2 (SGLT2) 저해제인 empagliflozin 은 신장에서 포도당이
재흡수 되는 것을 선택적으로 억제하여 소변으로의 포도당 배출을 증가시킨다. 이 경우, 증가된 …